Nimodipine

• UNSPSC Description:

  Nimodipine (BAY-e 9736) is an orally active, well-tolerated and light-sensitive dihydropyridine calcium antagonist. Nimodipine can be used for the research of cerebrovascular disorders[1].

• Target Antigen:

  Autophagy; Calcium Channel

• Type:

  Reference compound

• Related Pathways:

  Autophagy;Membrane Transporter/Ion Channel;Neuronal Signaling

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cardiovascular Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Nimodipine.html

• Purity:

  99.86

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=C(C)NC(C)=C(C(OC(C)C)=O)C1C2=CC=CC([N+]([O-])=O)=C2)OCCOC

• Molecular Weight:

  418.44

• References & Citations:

  [1]Langley, M.S., et al. Nimodipine. Drugs 37, 669–699 (1989).|[2] Marbacher S, et al. Prevention of delayed cerebral vasospasm by continuous intrathecal infusion of glyceroltrinitrate and nimodipine in the rabbit model in vivo. Intensive Care Med. 2008;34(5):932-938.|[3]Honn KV, et al. Inhibition of tumor cell-platelet interactions and tumor metastasis by the calcium channel blocker, nimodipine. Clin Exp Metastasis. 1984;2(1):61-72.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Clinical Information:

  Launched

• CAS Number:

  66085-59-4